PT Kimia Farma Tbk completed the acquisition of 56.77% stake in PT Phapros, Tbk from PT Rajawali Nusantara Indonesia for an enterprise value of IDR 1.4 trillion.
March 27, 2019
Share
PT Kimia Farma (Persero) Tbk (IDX:KAEF) agreed to acquire 56.77% stake in PT Phapros, Tbk (IDX:PEHA) from PT Rajawali Nusantara Indonesia on February 13, 2019. A total of 476.9 million shares will be acquired as part of the deal. The acquisition process is expected to be completed in the first quarter of 2019.
PT Kimia Farma (Persero) Tbk (IDX:KAEF) completed the acquisition of 56.77% stake in PT Phapros, Tbk (IDX:PEHA) from PT Rajawali Nusantara Indonesia for an enterprise value of IDR 1.4 trillion on March 27, 2019. As on March 27, 2019, PT Kimia Farma (Persero) Tbk signed a sale and purchase agreement to acquire 56.77% stake in PT Phapros, Tbk.
PT Phapros Tbk is an Indonesia-based pharmaceutical company. The Company's business pillars consist of branded/ethical prescription medicines: hospitals and pharmacies in addition to other healthcare institutions; over-the-counter drugs: pharmacies, retail; generic prescription drugs: government institutions and hospitals; toll-in manufacturing, and medical device. It offers medicines for cardiovascular and hematopoietic, gastrointestinal and hepatobiliary, hormone Genito, urinary endocrine and metabolic, vitamins and minerals nutrition, dermatology, local anesthesia, immune & allergy, and others. The Company's medical devices include ACS MB system, ACS FB and FB PS, Primary Hip Stem, INASHUNT Semilunar Flushing, BoneFill Ortho and NPC-STRIP G. Its branded drugs include Colkatriol 0.25 mcg 30 Cap, Diafac XR, Diafac 500 mg 10 tablets, Spirolactone 25 & 1, Dextamine Syrup 60 ml, Diapros Tablet, Proinfarction, anemone, Pladel, and others. The Company also operates calibration laboratory.
PT Kimia Farma Tbk completed the acquisition of 56.77% stake in PT Phapros, Tbk from PT Rajawali Nusantara Indonesia for an enterprise value of IDR 1.4 trillion.
PT PHAPROS, TBK 